The subject of this publication is the conclusion of non-exclusive discount agreements pursuant to § 130a (8) SGB V for medicinal products containing the active ingredient fluorouracil (ATC: D11AF05) within the framework of a so-called "open house model". Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or associations of pharmaceutical companies are offered the opportunity to conclude or join a rebate agreement in accordance with §130a para. 8 SGB V for the active substances listed under Section B. Interested pharmaceutical companies can request the participation documents and the respective contract from the contact address mentioned under I.1). The prerequisite for concluding a contract is that the interested pharmaceutical company submits the requested participation documents completed and signed in full.

Conclusion of non-exclusive rebate agreements pursuant to § 130a para. 8 SGB V for medicinal products with the active ingredient fluorouracil (ATC: D11AF05) with the possibility of concluding them at any time within the framework of a so-called "open-house model". A contract will be signed with each pharmaceutical company that meets the eligibility requirements. There is no exclusivity.

Membership or conclusion of the contract can take place at any time and under the same conditions. Individual contract negotiations will not be conducted. The earliest contract start date is 01.12.2023, after which the contract period is a maximum of 24 months. The contract ends on 30.11.2025 regardless of the beginning of the contract. Should AOK Saxony-Anhalt put out to tender exclusive contracts for the active substances during the term of the contract in accordance with the relevant procurement regulations, the contracts concluded within the framework of this publication will be terminated in accordance with the contractual provisions.

This publication is not a public contract within the meaning of Section 103 GWB or public procurement law. In order to ensure the greatest possible degree of transparency for the intended contracts, the publication is published in the supplement to the Official Journal of the European Union. In the absence of a corresponding publication form, the contract notice will be used. The resulting conceptual requirements, such as the process name "open process", are due solely to the use of this notice form and the publication platform. This is not associated with any further significance, in particular submission to procurement regulations, unless they are mandatory for legal reasons.